Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

[1]  H. Döhner,et al.  Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study , 2020, Leukemia.

[2]  U. Platzbecker.  Treatment of MDS. , 2019, Blood.

[3]  C. Schürch.  Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions , 2018, Front. Oncol..

[4]  C. Muñoz‐Calleja,et al.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets , 2018, Front. Immunol..

[5]  M. Minden,et al.  CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission , 2017, Blood Cancer Journal.

[6]  M. Sekeres,et al.  Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. , 2017, Annual review of medicine.

[7]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[8]  R. Komrokji.  Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. , 2015, Clinical lymphoma, myeloma & leukemia.

[9]  H. Ramshaw,et al.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.

[10]  U. Testa,et al.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.

[11]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[12]  B. Zhong,et al.  Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. , 2007, Blood.

[13]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[14]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[15]  M. Graf,et al.  Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies , 2004, European journal of haematology.

[16]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.